Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OCEA Stock Forecast 2026-2027
$0.01
Current Price
$1.93M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OCEA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
OCEA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-99.5%
From 52W High of $1.72
+60.0%
From 52W Low of $0.00
📊 TOP ANALYST CALLS
Did OCEA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ocean Biomedical is one of their latest high-conviction picks.
Latest OCEA Stock Price Targets & Analyst Predictions
OCEA has shown a year-to-date change of 0.0% and a 1-year change of 0.0%, reflecting flat performance over the past year. Comprehensive analyst forecasts are currently unavailable for OCEA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCEA Analyst Ratings
0
Buy
0
Hold
0
Sell
OCEA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.01
Latest OCEA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCEA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 31, 2023 | Taglich Brothers | Howard Halpern | Speculative Buy | Initiates | $20.00 |
| May 25, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $17.00 |
| Apr 27, 2023 | EF Hutton | Michael King | Buy | Maintains | $17.00 |
| Apr 13, 2023 | EF Hutton | Michael King | Buy | Reiterates | $10.00 |
| Mar 16, 2023 | Fundamental Research Corp. | Sid Rajeev | Buy | Initiates | $16.40 |
| Mar 13, 2023 | EF Hutton | Michael King | Buy | Initiates | $10.00 |
Ocean Biomedical Inc. (OCEA) Competitors
The following stocks are similar to Ocean Biomedical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ocean Biomedical Inc. (OCEA) Financial Data
Ocean Biomedical Inc. has a market capitalization of $1.93M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +9.7%.
Valuation Metrics
Market Cap
$1.93M
Enterprise Value
$0
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
0.0%
Current Ratio
0.1x
Debt/Equity
-0.2x
ROE
+9.7%
ROA
-114.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ocean Biomedical Inc. (OCEA) Business Model
About Ocean Biomedical Inc.
What They Do
Develops innovative therapeutics in life sciences.
Business Model
The company collaborates with research universities and medical institutions to transform scientific discoveries into clinical applications. It primarily generates revenue through the commercialization of these innovative therapeutics tailored for diseases with high unmet medical needs, such as oncology and infectious diseases.
Additional Information
Ocean Biomedical is positioned in a rapidly evolving healthcare market, focusing on advancing patient care and health outcomes through its development of viable medical treatments. This approach not only addresses critical therapeutic areas but also contributes to the broader landscape of medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. M. Michelle Berrey M.D., M.P.H.
Country
United States
IPO Year
2021
Website
www.oceanbiomedical.comOcean Biomedical Inc. (OCEA) Latest News & Analysis
Latest News
Quick Summary
Ocean Biomedical (NASDAQ: OCEA) reports positive research findings showing its cancer immunotherapy candidates synergize with tyrosine kinase inhibitors, enhancing treatment for non-small cell lung cancer.
Why It Matters
Ocean Biomedical's synergy between its immunotherapy and existing TKI treatments positions it favorably in the lucrative bispecific antibody market, potentially boosting its growth and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ocean Biomedical (NASDAQ: OCEA) secures additional NIH funding for malaria vaccine research. New FDA guidance may expedite development of their lipid-encapsulated vaccine approach.
Why It Matters
Ocean Biomedical's NIH funding boosts credibility and potential for its malaria vaccine, while FDA guidance could accelerate development, impacting future revenues and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) was notified by Nasdaq of non-compliance with listing rules due to the failure to file its Quarterly Report on Form 10-Q for Q3 2024.
Why It Matters
Ocean Biomedical's failure to file its 10-Q raises concerns about transparency and financial health, potentially leading to decreased investor confidence and stock price volatility.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) received a Nasdaq Staff Determination Letter for failing to file required financial reports. The company plans to appeal this decision to a Hearings Panel.
Why It Matters
Ocean Biomedical's failure to file required financial reports raises concerns about its financial health and transparency, potentially impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A license was secured for YKL-40 inhibitors, including lead molecule OAT-3912, showing promise in cancer and inflammatory diseases, along with a patent pending for a molecular screening test.
Why It Matters
The licensing of YKL-40 inhibitors, including OAT-3912, signals potential breakthroughs in treating cancers and inflammatory diseases, which could drive significant market interest and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ocean Biomedical has patent coverage for its Anti-CHI3L1, targeting various cancers, including Lung, Glioblastoma, Prostate, Melanoma, and Breast Cancer.
Why It Matters
Ocean Biomedical's patent coverage for anti-CHI3L1 indicates potential for diverse cancer treatments, which could drive future revenue and stock value growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OCEA Stock
What is Ocean Biomedical Inc.'s (OCEA) stock forecast for 2026?
Analyst forecasts for Ocean Biomedical Inc. (OCEA) are not currently available. The stock is trading at $0.01.
Is OCEA stock a good investment in 2026?
Analyst ratings for OCEA are not currently available. The stock is currently trading at $0.01. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCEA stock?
Price predictions from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is Ocean Biomedical Inc.'s business model?
The company collaborates with research universities and medical institutions to transform scientific discoveries into clinical applications. It primarily generates revenue through the commercialization of these innovative therapeutics tailored for diseases with high unmet medical needs, such as oncology and infectious diseases.
What is the highest forecasted price for OCEA Ocean Biomedical Inc.?
Price targets from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is the lowest forecasted price for OCEA Ocean Biomedical Inc.?
Price targets from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is the overall OCEA consensus from analysts for Ocean Biomedical Inc.?
Analyst ratings for OCEA are not currently available. The stock is trading at $0.01.
How accurate are OCEA stock price projections?
Stock price projections, including those for Ocean Biomedical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 5:14 PM UTC